William Edward Bondinell - Wayne PA Renee Louise DesJarlais - St. Davids PA Daniel Frank Veber - Ambler PA Dennis Shinji Yamashita - King of Prussia PA
The present invention provides bis-aminomethyl carbonyl protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Pagets disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.
The present invention provides compounds which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Pagets disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.
The present invention provides compounds which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Pagets disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.
The present invention provides Calkyl-4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease; and parasitic diseases, including malaria, by administering to a patient in need thereof one or more compounds of the present invention.
Yu Ru - Wayne PA, US Daniel Frank Veber - Ambler PA, US Maxwell David Cummings - Strafford PA, US Scott Kevin Thompson - Phoenixville PA, US Dennis Shinji Yamashita - Wayne PA, US
Assignee:
SmithKline Beecham Corporation - Philadelphia PA SmithKline Beecham p.l.c. - Brentford, Middlesex
The present invention provides 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.
Irina V. Shcherbakova - Salt Lake City UT, US Guangfei Huang - Alchua FL, US Otto Geoffroy - Alchua FL, US John Fox - Salt Lake City UT, US Robert Marquis - King of Prussia PA, US Dennis Shinji Yamashita - King of Prussia PA, US Juan Luengo - King of Prussia PA, US Wenyong Wang - King of Prussia PA, US
Maxwell D. Cummings - Strafford PA, US Yu Ru - Wayne PA, US Scott K. Thompson - Phoenixville PA, US Daniel F. Veber - Ambler PA, US Dennis S. Yamashita - Wayne PA, US
Assignee:
SmithKline Beecham Corporation - King of Prussia PA
The present invention provides Calkyl-4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease; and parasitic diseases, including malaria, by administering to a patient in need thereof one or more compounds of the present invention.
GSK - Boston and Philadelphia since Feb 2013
Entrepreneur in Residence, Discovery Partnerships with Academia
Trevena, Inc Mar 2008 - Feb 2013
VP and Head, Chemistry
GSK Aug 2001 - Mar 2008
Director, Center of Excellence Drug Discovery
GSK Sep 1998 - Aug 2001
Asst Director
GSK Jul 1995 - Sep 1998
Sr Investigator
Education:
Yale University 1986 - 1991
PhD, Organic Chemistry
Massachusetts Institute of Technology 1983 - 1986
BS, Chemistry
Skills:
Drug Discovery Medicinal Chemistry Chemistry Drug Development Organic Chemistry Pharmaceutical Industry Biotechnology Life Sciences Drug Design Organic Synthesis Clinical Development Pharmacology Immunology Lifesciences Analytical Chemistry Oncology Hplc Chromatography R&D Technology Transfer Lc Ms Molecular Biology Cro Biochemistry Mass Spectrometry Adme Assay Development Biopharmaceuticals Lead Change Nmr High Throughput Screening Lead Optimization Synthetic Chemistry Pharmaceuticals Intellectual Property Gpcrs